Clinical Trial Update: Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating toripalimab plus celecoxib for dMMR/MSI-H locally advanced colorectal cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer (CRC), PD-1 Inhibitor | Phase 2 | Status: RECRUITING